Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 2 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  2. US 12338242

    TYK2 inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  3. US 12338249

    Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  4. US 12319940

    Methods for purification of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  5. US 12312411

    Anti-CD38 binding domains

    Takeda Pharmaceutical Company Limited · Granted May 27, 2025 · Expires May 22, 2045

    granted
  6. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted May 20, 2025 · Expires May 15, 2045

    granted
  7. US 12295940

    Viral inhibitors, the synthesis thereof, and intermediates thereto

    Takeda Pharmaceutical Company Limited · Granted May 13, 2025 · Expires May 8, 2045

    granted
  8. US 12295941

    Viral inhibitors, the synthesis thereof, and intermediates thereto

    Takeda Pharmaceutical Company Limited · Granted May 13, 2025 · Expires May 8, 2045

    granted
  9. US 12298319

    Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators

    Takeda Pharmaceutical Company Limited · Granted May 13, 2025 · Expires May 8, 2045

    granted
  10. US 12291556

    Parathyroid hormone variants

    Takeda Pharmaceutical Company Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  11. US 12290531

    Compositions targeting BCMA and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  12. US 12286400

    Isofagomine salts, methods of use and formulations

    Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  13. US 12286479

    Treatment with anti-α4β7 antibody

    Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  14. US 12281073

    Substituted piperidine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted
  15. US 12257277

    Adeno-associated virus formulations

    Takeda Pharmaceutical Company Limited · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  16. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  17. US 12246047

    Adeno-associated virus purification methods

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  18. US 12240918

    Bispecific antibodies against plasma kallikrein and factor XII

    Takeda Pharmaceutical Company Limited · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  19. US 12221460

    Antibody drug conjugates

    Takeda Pharmaceutical Company Limited · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  20. US 12221441

    Plasma kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  21. US 12213989

    Use of maribavir in treatment regimens

    Takeda Pharmaceutical Company Limited · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  22. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  23. US 12209116

    Recombinant human C1 esterase inhibitor and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  24. US 12209138

    Anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted